Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Integrative Bioinformatics

Editor-in-Chief: Schreiber, Falk / Hofestädt, Ralf

Managing Editor: Sommer, Björn

Ed. by Baumbach, Jan / Chen, Ming / Orlov, Yuriy / Allmer, Jens

Editorial Board: Giorgetti, Alejandro / Harrison, Andrew / Kochetov, Aleksey / Krüger, Jens / Ma, Qi / Matsuno, Hiroshi / Mitra, Chanchal K. / Pauling, Josch K. / Rawlings, Chris / Fdez-Riverola, Florentino / Romano, Paolo / Röttger, Richard / Shoshi, Alban / Soares, Siomar de Castro / Taubert, Jan / Tauch, Andreas / Yousef, Malik / Weise, Stephan / Hassani-Pak, Keywan

4 Issues per year


CiteScore 2017: 0.77

SCImago Journal Rank (SJR) 2017: 0.336

Open Access
Online
ISSN
1613-4516
See all formats and pricing
More options …
Volume 8, Issue 3

Issues

A Relational Learning Approach to Structure-Activity Relationships in Drug Design Toxicity Studies

Rui Camacho / Max Pereira / Vítor Santos Costa
  • CRACS-INESC Porto, http://cracs.fc.up.pt/, Portugal
  • DCC/FCUP Universidade do Porto, http://www.dcc.fc.up.pt/, Portugal
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Nuno A. Fonseca / Carlos Adriano / Carlos J. V. Simões
  • Center for Neuroscience and Cell Biology (CNC), University of Coimbra, http://www.cnbc.pt/, Portugal
  • Chemistry Department, University of Coimbra, http://www.uc.pt/fctuc/dquimica/, Portugal
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Rui M. M. Brito
  • Center for Neuroscience and Cell Biology (CNC), University of Coimbra, http://www.cnbc.pt/, Portugal
  • Chemistry Department, University of Coimbra, http://www.uc.pt/fctuc/dquimica/, Portugal
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2016-10-18 | DOI: https://doi.org/10.1515/jib-2011-182

Summary

It has been recognized that the development of new therapeutic drugs is a complex and expensive process. A large number of factors affect the activity in vivo of putative candidate molecules and the propensity for causing adverse and toxic effects is recognized as one of the major hurdles behind the current “target-rich, lead-poor” scenario.

Structure-Activity Relationship (SAR) studies, using relational Machine Learning (ML) algorithms, have already been shown to be very useful in the complex process of rational drug design. Despite the ML successes, human expertise is still of the utmost importance in the drug development process. An iterative process and tight integration between the models developed by ML algorithms and the know-how of medicinal chemistry experts would be a very useful symbiotic approach. In this paper we describe a software tool that achieves that goal - iLogCHEM. The tool allows the use of Relational Learners in the task of identifying molecules or molecular fragments with potential to produce toxic effects, and thus help in stream-lining drug design in silico. It also allows the expert to guide the search for useful molecules without the need to know the details of the algorithms used. The models produced by the algorithms may be visualized using a graphical interface, that is of common use amongst researchers in structural biology and medicinal chemistry. The graphical interface enables the expert to provide feedback to the learning system. The developed tool has also facilities to handle the similarity bias typical of large chemical databases. For that purpose the user can filter out similar compounds when assembling a data set. Additionally, we propose ways of providing background knowledge for Relational Learners using the results of Graph Mining algorithms.

About the article

Published Online: 2016-10-18

Published in Print: 2011-12-01


Citation Information: Journal of Integrative Bioinformatics, Volume 8, Issue 3, Pages 176–194, ISSN (Online) 1613-4516, DOI: https://doi.org/10.1515/jib-2011-182.

Export Citation

© 2011 The Author(s). Published by Journal of Integrative Bioinformatics.. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. BY-NC-ND 4.0

Comments (0)

Please log in or register to comment.
Log in